SGMO

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Sangamo Therapeutics advanced its rolling BLA submission to the FDA for ST-920 in Fabry diseaseMar 9, 2026
• Sangamo Therapeutics initiates rolling BLA submission to FDA for ST-920 in Fabry diseaseDec 18, 2025
• Sangamo Therapeutics receives U.S. FDA Fast Track designation for ST-503 for treatment of small fiber neuropathyDec 2, 2025
• Sangamo Therapeutics announces FDA acceptance of BLA rolling submission request for ST-920 in Fabry diseaseNov 21, 2025
• Sangamo Therapeutics announces positive topline results from STAAR registration study in Fabry diseaseJun 24, 2025